We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
The latest trading session saw Astrazeneca (AZN - Free Report) ending at $71.93, denoting a -1.24% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.41% for the day. Meanwhile, the Dow experienced a rise of 0.08%, and the technology-dominated Nasdaq saw an increase of 0.67%.
Shares of the pharmaceutical witnessed a gain of 0.54% over the previous month, beating the performance of the Medical sector with its loss of 3.74% and underperforming the S&P 500's gain of 6.13%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. On that day, Astrazeneca is projected to report earnings of $1.11 per share, which would represent year-over-year growth of 12.12%. Our most recent consensus estimate is calling for quarterly revenue of $14.03 billion, up 8.42% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $4.49 per share and a revenue of $57.68 billion, demonstrating changes of +9.25% and +6.67%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.35% lower. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold).
In terms of valuation, Astrazeneca is currently trading at a Forward P/E ratio of 16.2. This valuation marks a discount compared to its industry's average Forward P/E of 20.51.
It is also worth noting that AZN currently has a PEG ratio of 1.34. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. AZN's industry had an average PEG ratio of 1.47 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
The latest trading session saw Astrazeneca (AZN - Free Report) ending at $71.93, denoting a -1.24% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.41% for the day. Meanwhile, the Dow experienced a rise of 0.08%, and the technology-dominated Nasdaq saw an increase of 0.67%.
Shares of the pharmaceutical witnessed a gain of 0.54% over the previous month, beating the performance of the Medical sector with its loss of 3.74% and underperforming the S&P 500's gain of 6.13%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. On that day, Astrazeneca is projected to report earnings of $1.11 per share, which would represent year-over-year growth of 12.12%. Our most recent consensus estimate is calling for quarterly revenue of $14.03 billion, up 8.42% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $4.49 per share and a revenue of $57.68 billion, demonstrating changes of +9.25% and +6.67%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.35% lower. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold).
In terms of valuation, Astrazeneca is currently trading at a Forward P/E ratio of 16.2. This valuation marks a discount compared to its industry's average Forward P/E of 20.51.
It is also worth noting that AZN currently has a PEG ratio of 1.34. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. AZN's industry had an average PEG ratio of 1.47 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.